Isolated limb perfusion with tumour necrosis factor-α and melphalan with or without interferon-γ; for the treatment of in-transit melanoma metastases
D. Liénard, Ferdy J. Lejeune, S Hiemstra(Centre Hospitalier Universitaire Vaudois), Alexander M.M. Eggermont(University Medical Center Utrecht), Julie Clarke(Centre Hospitalier Universitaire Vaudois), Gerhard Steinmann(Boehringer Ingelheim (Germany)), F. Rosenkaimer(Centre Hospitalier Universitaire Vaudois), G.D.W Towse(Centre Hospitalier Universitaire Vaudois), P.I.M. Schmitz(Centre Hospitalier Universitaire Vaudois), Bin K. Kroon(Centre Hospitalier Universitaire Vaudois), Heimen Schraffordt Koops
Cited by 148
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k